trending Market Intelligence /marketintelligence/en/news-insights/trending/gplbxZ3bVkEz3pevSTm3aQ2 content esgSubNav
In This List

Trillium closes common, preferred stock offering

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Trillium closes common, preferred stock offering

Trillium Therapeutics Inc. closed an underwritten public offering of 2,750,000 common shares and 3,250,000 series II nonvoting convertible first preferred shares at $5 apiece with gross proceeds of $30 million.

The company plans to use the net proceeds to advance and expand the current phase 1 trial of SIRPaFc in patients with advanced hematologic malignancies, as well as the solid tumor phase 1 trial of SIRPaFc in patients with relapsed and refractory, percutaneously accessible cancers through the dose escalation and expansion phases.

In addition, Trillium will use the proceeds to initiate and conduct a phase 1 trial for TTI-622, with dose escalation and expansion phase focused on combination treatment and for general corporate and working capital purposes.

Cowen acted as the sole book-running manager for the offering, with Ladenburg Thalmann as co-manager.